Researchers gained insight into how some patients develop resistance to CD20-targeted immunotherapies for certain blood cancers and describe how their findings might offer alternative treatment options.
Oncogenes such as MYC are notorious troublemakers that promote cancer. Previous research strategies have focused on finding ways to quiet down levels of MYC; however, basic scientists at Children’s Hospital of Philadelphia took the opposite approach.
